Resverlogix Corp. (TSE:RVX – Get Free Report)’s share price hit a new 52-week low on Tuesday . The company traded as low as C$0.09 and last traded at C$0.09, with a volume of 31600 shares changing hands. The stock had previously closed at C$0.09.
Resverlogix Stock Down 5.6%
The company has a quick ratio of 0.04, a current ratio of 0.04 and a debt-to-equity ratio of -82.47. The company’s fifty day moving average is C$0.10 and its 200-day moving average is C$0.10. The company has a market cap of C$29.26 million, a PE ratio of -2.12 and a beta of 0.12.
About Resverlogix
Founded in 2001, Resverlogix is a Calgary based late-stage biotechnology company, and a world leader in epigenetics, with the goal of developing first-in-class therapies for the benefit of patients with chronic disease. Resverlogix is developing a new class of epigenetic therapies designed to regulate the expression of disease-causing genes. We aim to improve patients’ lives by restoring biological functions – altered by serious illnesses such as cardiovascular disease – back to a healthier state.
Further Reading
- Five stocks we like better than Resverlogix
- Meta’s Muse Highlights Arm’s Growing Role in AI Infrastructure
- Oura’s $15.6 Billion IPO Is Betting Investors See More Than a Smart Ring
- AMD Chips Away at NVIDIA’s AI Throne
- Is the Fed Playing Chess With Rates—Or Just Behind the Curve Again?
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.
